Rasonque, Revolution’s pancreatic cancer drug, sees major launch
The company reported $197.6 million in third-quarter product revenue after roughly five weeks of U.S. sales for Rasonque.
TL;DR
- Revolution Medicines reported $197.6 million in third-quarter product revenue for Rasonque.
- The launch began after U.S. approval of daraxonrasib for eligible metastatic pancreatic cancer patients.
- The company said more than 5,000 unique patients received the drug in the United States through September 30.
STAT described the initial commercial launch as unusually strong, citing nearly $198 million in sales over about five weeks. The headline’s characterization is the outlet’s assessment of launch scale. [1]
Revolution Medicines’ quarterly release reported $197.6 million in product revenue and said more than 5,000 unique U.S. patients received commercial Rasonque through September 30, 2026. [2]
The company also reported a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in October, a step toward potential European Union approval. That opinion is not a final European Commission authorization. [2]
The short launch window limits what can be inferred about durable demand, access or the eventual revenue trajectory. The earnings release is company-reported information; longer follow-up and independent market data are not yet available here. [1]
Why it matters
The launch offers an early commercial readout for a newly approved precision oncology drug and may shape expectations for access and future development of RAS-targeted therapies. Five weeks of sales are too brief to establish a sustained trend.
Editor's note
Commercial figures are company-reported. The EMA committee opinion is a recommendation step, not final EU authorization. No patient advice.